FDA.reportPublic FDA data

KRAZATI 200 MG Oral Tablet

RxCUI
2625923
RxNorm name
KRAZATI 200 MG Oral Tablet
Display name
KRAZATI 200 MG Oral Tablet
Full name
KRAZATI 200 MG Oral Tablet
Term type
PSN
Status
DailyMed mapping
Updated
2026-06-04 23:38:46

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
KRAZATIADAGRASIBMirati Therapeutics, Inc0b8bf078-34c2-4f45-9012-38a8ac082b012026-03-25Warnings, Adverse reactionsExact identifier
rxcui: 2625923

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
0b8bf078-34c2-4f45-9012-38a8ac082b01KRAZATI 200 MG Oral Tablet [PSN] · adagrasib 200 MG Oral Tablet [Krazati] [SBD] · Krazati 200 MG Oral Tablet [SY]313These highlights do not include all the information needed to use KRAZATI safely and effectively. See full prescribing information for KRAZATI. KRAZATI ® (adagrasib) tablets, for oral use Initial U.S. Approval: 202220260325